Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Disease
Rosiglitazone did not affect flow-mediated dilation of brachial artery
September 27th, 2004
Rosiglitazone did not affect flow-mediated dilation (FMD) of the brachial artery in men with coronary artery disease without diabetes. "Recent data have shown that peroxisome proliferator-activated receptor-gamma agonists may exert protective effects on the vascular endothelium by amelioration of insulin resistance and through direct anti-inflammatory effects. In this study we assessed the effect of rosiglitazone on biochemical and biophysical indexes of endothelial function in male, nondiabetic patients with coronary artery disease. Consecutive male subjects (n=71) with clinically stable, angiographically documented coronary artery disease and without diabetes mellitus...
Source: Diabetes Week (2004-09-27)
|
